Roche Diagnostics launches new assays for early detection of Preeclampsia, a serious pregnancy complication. A first in Canada!
The Elecsys PlGF and sFlt-1 immunoassays are the first Health Canada approved and available automated diagnostic test of preeclampsia. A simple blood test can now deliver clear, reliable results with a specificity of 95% and a sensitivity of 82% to help identify patients at risk for potentially life threatening complications. This is particularly important to pregnant women but also has implications for the unborn child.
The new Elecsys PlGF and sFlt-1 immunoassays are a major advance in preeclampsia diagnosis that has remained virtually unchanged for decades since it was relying on variable clinical features such as hypertension and proteinuria.
Preeclampsia is a serious complication of pregnancy characterized by hypertension and proteinuria appearing around the 20th week of gestation. It occurs in 3-5% of pregnancies and results in substantial maternal and fetal or neonatal mortality or morbidity. Clinical manifestations can vary from mild to severe forms. Women suffering from hypertension, diabetes mellitus, obesity or underlying renal disease, to name a few, are considered as high risk.
“The Elecsys PlGF and sFlt-1 immunoassays provide an objective aid in the diagnosis of preeclampsia.” commented Christopher Parker, President and General Manager, Roche Diagnostics Canada. “The availability of these new assays represent an important milestone for women’s health in Canada”.
The new Elecsys PlGF and sFlt-1 immunoassays can run on Roche Diagnostics Elecsys® 2010, MODULAR® E170, cobas e 411 and cobas e 601. The test results are available in 18 minutes. Roche’s new assays improve outcome for mother and child through effective clinical management.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com and www.rochecanada.com.
All trademarks used or mentioned in this release are legally protected.
For further information please contact:
Tel. : 450 686 5500